Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Decades of research on genetic mutations have had one overriding goal: to understand how specific mutations interfere with physiological processes and promote disease. Adrestia Therapeutics, a spin-out of the University of Cambridge in the UK, is taking a new tack. Rather than looking at how mutations cause illness, they are scouring the genome for mutations that keep people healthy despite a genetic predisposition to disease. The idea is that mutations that put an individual at high risk of developing a disease can be overridden by mutations elsewhere in the genome. This phenomenon, called ‘synthetic rescue’, holds out the tantalizing possibility of providing an entirely new strategy for discovering therapeutic targets and drugs.